drugset / Trial / NCT01440166

Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers

NCT01440166

Phase 1 Completed 52 enrolled Catabasis Pharmaceuticals
RandomizedParallel-groupDouble-blind

Summary

* To evaluate the safety and tolerability of escalating single doses of CAT-1004 relative to placebo in healthy adult volunteers. * To evaluate the pharmacokinetics (PK) of escalating single doses of CAT-1004 in healthy adult volunteers. * To evaluate the effect of a high-fat meal on single doses of CAT-1004 in healthy adult volunteers.

Timeline

Start
2011-09
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Edasalonexent Small molecule Oral

Indications

No indication recorded.